[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Groupe Hospitalier Diaconesses Croix Saint-Simon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":199},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,69,97,120,144,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100651044","change-in-shoe-size-and-forefoot-morphological-parameters-after-scarf--p1-osteotomy-for-hallux-valgus-a-prospective-study-using-surface-3d-scanning-100651044",false,"NCT07755488","Change in Shoe Size and Forefoot Morphological Parameters After Scarf + P1 Osteotomy for Hallux Valgus: a Prospective Study Using Surface 3D Scanning","Changes in Shoe Size and Forefoot Morphological Parameters After Scarf + P1 Osteotomy for Hallux Valgus: A Prospective Study Using Surface 3D Scanning","POINTURE-HV","Inclusion Criteria:\n\n* Patient informed about the study and signed written consent obtained in duplicate\n* Male or female participant aged 18 years or older\n* Symptomatic hallux valgus without lateral ray involvement, requiring surgical correction by Scarf + P1 osteotomy\n* Primary surgery planned for the affected foot\n* Ability to understand study information, complete questionnaires, and comply with follow-up visits (6 weeks and 6 months)\n\nExclusion Criteria:\n\n* Previous bony surgery of the first ray or forefoot on the affected side (osteotomy, arthrodesis)\n* Surgical indication on lateral rays (claw toes, Weil osteotomy)\n* Severe lower-limb neurological or vascular disease altering gait or foot morphology (Charcot foot, critical limb ischemia, severe neuropathy)\n* Active inflammatory rheumatic disease (e.g., rheumatoid arthritis) with polyarticular foot involvement\n* Complex foot deformity requiring primary first metatarsophalangeal (MTP1) arthrodesis or procedure other than Scarf + P1 osteotomy\n* Pregnant or breastfeeding woman\n* Person under legal guardianship or unable to provide free and informed consent\n* Person deprived of liberty by judicial or administrative decision\n* Concurrent participation in another research study that could interfere with study endpoints","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background and Rationale:\n\nSurgical correction of Hallux Valgus via Scarf and P1 osteotomy aims to realign the first ray, modifying overall forefoot morphology. While radiological correction is well established, a discrepancy often exists between objective foot measurements and patient-perceived postoperative shoe fitting. Weight-bearing 3D surface scanning provides a non-irradiating, precise method to evaluate volumetric and dimensional changes without the biases of traditional foot-measuring gauges.\n\nObjective and Hypothesis:\n\nThe primary objective is to measure changes in shoe size (in French\u002FParis points) using weight-bearing 3D surface scanning between baseline and 6 months postoperatively. The study hypothesis is that Scarf + P1 osteotomy induces a shoe size reduction of at least 0.5 Paris points at 6 months, correlated with forefoot width reduction, M1 shortening, and angular correction (HVA and M1-M2 angles).\n\nStudy Design:\n\nProspective, single-center, non-comparative interventional study with minimal risks and constraints (RIPH 2) involving 100 participants.",[27],"Hallux Valgus",[27,29,30,31,32],"Scarf Osteotomy","3D Surface Scanner","Shoe Size","Forefoot Morphometry","NOT_YET_RECRUITING","2026-08-05",{"date":36,"type":37},"2026-08-10","ACTUAL",{"date":39,"type":21},"2026-09-20",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Groupe Hospitalier Diaconesses Croix Saint-Simon","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100650543","skin-closure-in-prosthetic-joint-surgery-comparative-evaluation-of-the-barbed-sutures-and-skin-glue-technique-cica-pro-100650543","NCT07749495","Skin Closure in Prosthetic Joint Surgery: Comparative Evaluation of the \"Barbed Sutures and Skin Glue\" Technique (Cica-Pro)","Cica-Pro","Inclusion Criteria:\n\n* Men and women aged over 18 years\n* Patient who has provided written informed consent in duplicate\n* Patient scheduled for a primary hip or knee prosthesis implantation\n* BMI \\\u003C 30 kg\u002Fm²\n* Non-smoker or smoking cessation for more than 4 weeks\n* Patient able to read and understand French\n* Patient with sufficient cognitive capacity to strictly follow study instructions (completion of the calendar)\n\nExclusion Criteria:\n\n* Patient expresses opposition to participating in the study\n* Patients under 18 years of age\n* Patient scheduled for prosthesis revision surgery\n* History of osteoarticular or soft-tissue infection\n* Diabetes, cardiovascular disease, immunodeficiency, or immunosuppressive treatment\n* Consumption of drugs, tobacco, or alcohol\n* Allergy to nickel (staples) or adhesive\n* History of anxiety disorders (generalized anxiety disorder, panic disorder, specific phobia, agoraphobia, social anxiety, separation anxiety), obsessive compulsive disorder (OCD), or post-traumatic stress disorder (PTSD)\n* Patient unable to read and\u002For understand French\n* Individuals deprived of liberty by judicial or administrative decision\n* Adults unable to consent or incapable of expressing consent\n* Subjects not affiliated with or not benefiting from a social security scheme\n* Pregnant or breastfeeding women",{"count":53,"type":21},400,[24],"The choice of skin closure (staples vs. monofilament sutures vs. barbed sutures\u002Fadhesive) is critical for wound healing quality in prosthetic surgery (hip and knee). The combination of barbed sutures (e.g., Stratafix) and skin glue (e.g., Dermabond) is promising (superior cosmetic outcome, no suture removal, antimicrobial barrier) but has been poorly evaluated prospectively and comparatively in orthopaedics, which justifies this study. The primary objective is to compare the wound healing success rate at two weeks postoperatively between the patient groups. The primary outcome measure is successful wound healing, defined as the absence of wound complications (wound dehiscence, seroma, hematoma, early postoperative infection) during the first two weeks",[57,58,59],"Surgical Wound","Knee Arthroplasty","Hip Arthroplasty",[61],"Skin Closure in Prosthetic Joint Surgery",{"date":63,"type":37},"2026-08-06",{"date":65,"type":21},"2026-10-15",{"date":67,"type":21},"2027-12",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100639531","total-knee-arthroplasty-with-personalized-implantation-computer-navigation-assisted-surgery-versus-robotic-assisted-surgery-100639531","NCT07574762","Total Knee Arthroplasty With Personalized Implantation: Computer Navigation-Assisted Surgery Versus Robotic-Assisted Surgery","Total Knee Replacement With Personalized Implantation Navigation-assisted Surgery Versus Robotic Assistance \"CAN-ARD\"","CAN-ARD","Inclusion Criteria:\n\n* Patient providing written informed consent according to regulatory requirements\n* Male or female patients aged ≥18 years\n* Patients undergoing primary total knee arthroplasty for osteoarthritis\n* Use of Attune® prosthesis with posterior cruciate ligament retention (CR) and patellar resurfacing\n\nExclusion Criteria:\n\n* History of ligament reconstruction\n* Previous fracture or bone surgery (osteotomy) of the ipsilateral femur or tibia (except hip or ankle surgery)\n* Preoperative knee stiffness with flexion contracture \\>15° or flexion \\\u003C90°\n* Individuals deprived of liberty by judicial or administrative decision\n* Patients not affiliated with a social security system\n* Patients unable to understand French\n* Patients with cognitive impairment\n* Patients whose place of residence makes close clinical follow-up impossible -- Women of childbearing potential without effective contraception\n* Pregnant or breastfeeding women",{"count":78,"type":21},140,[24],"Title: Personalized Total Knee Arthroplasty: Computer-Assisted Navigation vs. Robotic Assistance (CAN-ARD).\n\nSummary:\n\nKnee osteoarthritis is frequently treated with Total Knee Arthroplasty (TKA). However, approximately 20% of patients remain dissatisfied following the procedure. This study aims to compare two surgical assistance technologies designed to improve prosthetic placement accuracy: Computer-Assisted Navigation (CAN) and Robotic-Arm Assistance (RA).\n\nThe primary objective is to determine if there is a significant difference in functional outcomes and the \"forgotten joint\" sensation (measured by the Forgotten Joint Score - FJS) between patients operated on with robotic assistance versus those with traditional navigation at 3, 12, and 24 months post-surgery. The study's hypothesis is that there is no major clinical difference between these two techniques when applied within a personalized alignment strategy.",[82],"Osteoarthritis",[84,85,86,82],"Robotic","Navigation","Arthroplasty","RECRUITING","2026-05-05",{"date":90,"type":37},"2026-05-08",{"date":92,"type":37},"2026-01-26",{"date":94,"type":21},"2029-01-26",{"name":43,"class":44},1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":96},"100583139","phase-3-evaluation-of-the-efficacy-of-therapeutic-infiltrations-of-the-pudendal-nerve-performed-under-neurostimulation-on-pain-1-month-after-an-infiltration-of-local-anaesthetic-in-the-treatment-of-pudendal-neuralgia-100583139","NCT06872437","Evaluation of the Efficacy of Therapeutic Infiltrations of the Pudendal Nerve, Performed Under Neurostimulation on Pain, 1 Month After an Infiltration of Local Anaesthetic, in the Treatment of Pudendal Neuralgia.","EFFICACY OF THE USUAL TREATMENT WITH INFILTRATION OF LOCAL ANAESTHETIC IN THE TREATMENT OF PUDENDAL NEURALGIA: A RANDOMISED TRIAL COMPARED WITH A PHYSIOLOGICAL SERUM","EPHI-DACI","Inclusion Criteria:\n\n* Patient 18 years of age or older,\n* Expressed consent to participate in the study\n* Affiliated or beneficiary of a social security plan\n* With pudendal neuralgia (Nantes criteria \"modified\" Nantes criteria).\n* MRI normal or without pathology explaining the pain\n* Drug treatment failure as defined in the LOS, i.e., failure (VAS decrease \\\u003C 3) of at least one antiepileptic drug and an antidepressant whose dosages have been to the maximum possible dosage, or in whom a side effect for whom a side effect could not allow the dose to be increased to its to its maximum allowed dose.\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman\n* General and\u002For local infection (fistulous or cutaneous suppuration of the anal margin) in progress\n* Known neurological pathology that may explain the pain\n* Psychiatric pathology requiring a drug treatment treatment\n* Anticoagulants or haemostasis disorders\n* Hypersensitivity to lidocaine hydrochloride, to local anesthetics\n* Recurrent porphyrias",{"count":106,"type":21},60,[108],"PHASE3","Pudendal neuralgia (PN) is a chronic nerve compression syndrome causing neuropathic pain. Treatment includes medication, infiltration and decompressive surgery. Medicinal treatment involves the use of drugs that have proved effective in other areas, such as shingles or diabetes. There is no consensus on the molecules to be used for pudendal nerve infiltration (PNTI), and less than half of patients experience short-term relief. The only risk factor for failure is the duration of pain. Our study proposes to compare the usual treatment with a placebo, as no type of infiltration has been compared with a placebo.",[111],"Pudendal Neuralgia","2025-05-16",{"date":114,"type":37},"2025-05-18",{"date":116,"type":37},"2023-12-08",{"date":118,"type":21},"2029-03-08",{"name":43,"class":44},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":103,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":96},"100562375","efficacy-of-usual-management-of-chronic-idiopathic-ano-perineal-pain-by-using-local-anesthetic-infiltration-100562375","NCT06602349","EFFICACY of USUAL MANAGEMENT of CHRONIC IDIOPATHIC ANO-PERINEAL PAIN by USING LOCAL ANESTHETIC INFILTRATION","EFFICACY of USUAL MANAGEMENT of CHRONIC IDIOPATHIC ANO-PERINEAL PAIN by USING LOCAL ANESTHETIC INFILTRATION : a RANDOMIZED DOUBLE-BLIND SALINE-CONTROLLED TRIAL","Inclusion Criteria:\n\n* Patient 18 years of age or older,\n* Express consent to participate in the study\n* Affiliated or beneficiary of a social security plan\n* Presenting chronic idiopathic ano-perineal pain\n* MRI normal or without pathology explaining pain (Multidisciplinary consultation meeting reread if in doubt)\n* Resistance to \\"standard\\" 1st-line medical treatment (level 1 or 2 analgesics and\u002For non-steroidal anti-inflammatory and\u002For local topicals)\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant or breast-feeding woman\n* General and\u002For local infection (fistulous or cutaneous suppuration of anal margin) in progress\n* Known neurological pathology that may explain pain\n* Psychiatric pathology requiring medication\n* Anticoagulants or haemostasis disorders\n* Hypersensitivity to lidocaine hydrochloride or local anesthetics\n* Recurrent porphyrias",{"count":106,"type":21},[24],"The goal of this clinical trial is to evaluate the efficacy of a posterior perineal block performed under neurostimulation at 1 month after local anesthetic infiltration in the treatment of chronic idiopathic ano-perineal pain.\n\nThe main questions aims to answer are :\n\n1. The efficacy of a posterior perineal block performed under neurostimulation on pain 1 month after local anesthetic infiltration in the treatment of chronic idiopathic ano-perineal pain.\n2. The rate of maintenance at 3 months of a positive response to the first infiltration.\n3. The pain-free rate at 1 month after the first infiltration.\n4. Evolution of quality of life and pain impact between inclusion and one month after the first infiltration.\n5. Changes in anxiety and depressive disorders associated with pain between inclusion and one month after the first infiltration.\n6. The evolution of symptoms related to central sensitization (both somatic and emotional) between inclusion and one month after the first infiltration.\n\nParticipants will :\n\n* be managed with a posterior perineal block of lidocaine or saline solution under neurostimulation.\n* complete a questionnaire on pain, anxiety and depression at inclusion and one month after injection of the research product (lidocaine or saline solution).\n\nResearchers will compare between the two treatment arms (lidocaine versus saline solution) to see the rate of patients with a reduction of at least 3 points on a visual analog pain scale between inclusion and 1 month after the first injection.",[131],"Chronic Idiopathic Anopérineal Pain",[133,134,135,136,137],"LIDOCAINE","posterior perineal block","randomized, double-blind","Salin solution","chronic idiopathic ano-perineal pain","2024-09-30",{"date":140,"type":37},"2024-10-01",{"date":116,"type":37},{"date":118,"type":21},{"name":43,"class":44},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":96},"100270533","cohort-of-prosthetic-joint-infections-100270533","NCT02801253","Cohort of Prosthetic Joint Infections","Prospective Cohort of Patients With Prosthetic Joint Infection","COPINS","Inclusion Criteria:\n\n* Patient aged over 18 years old with hip, knee and or shoulder joint prosthesis who consented to participate in the study with:\n* According to musculoskeletal infection society definition: PJI is present when one of the major criteria exists or four out of six minor criteria.\n\nMajor Criteria:\n\n* Two positive periprosthetic cultures with phenotypically identical organisms, OR\n* A sinus tract communicating with the joint, OR\n\nMinor Criteria:\n\n* Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)\n* Elevated synovial fluid white blood cell (WBC)\n* Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)\n* The presence of pus in the joint without known cause\n* Positive histological analysis of periprosthetic tissue\n* A single positive culture\n\nOr a PJI which meets the following three criteria:\n\n* Medical story suggesting prosthetic joint infection.\n* The presence of pain either with or without swelling for more than 3 months unrelated to a mechanical cause.\n* Germ identification in a single sample of fluid aspiration or tissue culture.\n\n  * Or microbial growth in prosthesis sonication fluid culture greater than 50CFU\u002Fml.\n\nExclusion Criteria:\n\n* Patient who does not meet eligibility criteria.\n* Patient lawfully deprived of his liberty.\n* Patient not insured under social security scheme.",{"count":153,"type":21},800,"OBSERVATIONAL","Management of prosthetic joint infections (PJI) is a challenging task. These infections include different clinical and microbiological settings calling upon various treatment strategies according to infection type (acute or chronic), bone quality, the involved micro-organism and the patient's general condition and willing.\n\nTreatment of PJI combines surgery and prolonged antibiotic therapy. In some patients with a high operative risk prolonged suppressive antibiotic therapy can be used.\n\nLack of large prospective studies motivated the conception of this cohort with a long term follow up, regardless to PJI management procedures.",[157],"Prosthetic Joint Infection","2022-03-28",{"date":160,"type":37},"2022-03-29",{"date":162,"type":37},"2015-09-11",{"date":164,"type":21},"2029-09",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":174,"minAge":18,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":5},"100287730","phase-2-two-therapeutic-strategies-in-first-line-in-patients-with-epithelial-advanced-ovarian-cancer-100287730","NCT03025477","Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer","Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer","CHIMOVIP","Inclusion Criteria:\n\n* Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to be performed in patients with pleural effusion.\n* Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion\n* Age ≥18 and \\\u003C 75 years old.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score \\\u003C 6 in patients \\> 70 years old).\n* Adequate blood count (test realized in the past 14 days before inclusion) : neutrophils \\> 1500\u002Fmm3, platelets \\> 150 000\u002Fmm3.\n* Creatinine clearance MDRD ≥ 60 mL\u002Fmin\n* Registration in a national health care system (CMU included).\n* Signed and dated informed consent.\n\nExclusion Criteria:\n\n* FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion.\n* Patient having received previous chemotherapy for ovarian cancer.\n* Left ventricular ejection fraction \\\u003C 50% before chemotherapy initiation\n* Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted)\n* Concomitant administration of prophylactic phenytoin or live attenuated viral vaccines such as yellow fever vaccine,\n* Patients with known hypersensitivity to any component of study drug\n* Patients without motivation or capacity to respect study requirements and constraints\n* Pregnancy or breast feeding women","FEMALE","75 Years",{"count":177,"type":21},84,[179],"PHASE2","CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.",[182],"Ovarian Cancer, Epithelial",[184,185,186,187,188,189,190],"Intraperitoneal","Intravenous","Completeness of cytoreduction score","Carboplatin","Epirubicin","Paclitaxel","Cisplatin","2021-02-10",{"date":193,"type":37},"2021-02-11",{"date":195,"type":37},"2016-10",{"date":197,"type":21},"2032-10",{"name":43,"class":44},""]